Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsGuangzhou, China -- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of innovativetherapies and biosimilars, today announced that dosinghas begun in Phase IA/IIB clinical trial to study efficacy and safety of BAT6026 inpatients with moderate to sever...
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of innovativetherapies and biosimilars, today announced the company has reached a licensing agreement with Macter International Ltd. for BAT 17 06, its bevacizumab biosimilar, unde...
Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
